A former airport spa operator's testing subsidiary is now responsible for screening travelers for Ebola at U.S. airports and responding to the outbreak in Congo, under two federal awards that the company and the government's own contract data describe in conflicting terms. XpresTest, a subsidiary of XWELL, holds an $18.8 million Centers for Disease Control and Prevention contract for Ebola entry screening and a $20 million State Department award for outbreak response in the Democratic Republic of Congo, MedicalDaily reported Nov. 11, citing a ProPublica investigation published Nov. 9. Together the awards are worth nearly $40 million, about seven times what the company had previously received directly in federal contracts.

The chief executive of XpresTest's parent company has been candid about the stakes. "This is a risky contract. I'm not sure we can do it," said Ezra Ernst, CEO of XWELL, according to MedicalDaily's account of the ProPublica report.

Who Is XpresTest, and Why Is It Screening for Ebola?

XWELL, formerly XpresSpa Group, was founded in 2006 as an airport spa company. During the COVID-19 pandemic it received $5.5 million from the CDC to offer travelers COVID-19 testing, and XpresTest built years of experience monitoring for COVID-19 and other diseases at U.S. airports for the government.

What XpresTest lacks is Ebola experience. The company has never worked on Ebola or provided biosecurity services abroad, according to the ProPublica reporting summarized by MedicalDaily. Ernst called the international work "a new thing for us."

That gap drew criticism from Jeremy Konyndyk, who helped oversee the U.S. response to the 2014 West Africa Ebola outbreak. "I have to wonder why the hell they're not going with someone who has actually done this before," he told ProPublica.

Sole-Source or Competitive? Two Accounts of the $18.8M CDC Award

The sharpest open question concerns how the CDC chose XpresTest. Ernst said the company won both contracts through competitive bidding. Federal contract data compiled by HigherGov describe the CDC award differently, listing it as a sole-source contract justified by urgency, with one bid received and a potential value of about $35.5 million. MedicalDaily said it could not reconcile the two accounts, and the CDC did not respond to ProPublica's request for comment.

The gap between the $18.8 million figure and the roughly $35.5 million potential value in the contract data also matters. The larger number is a potential value, not money obligated. Ernst himself raised the possibility that the government could shift priorities and pay only a fraction of the contract. XWELL did not announce either award, and Ernst cited several reasons, including that "none of these contracts are guaranteed."

The State Department characterized its own award differently from the CDC data. The department said its award came through "a competitive process that builds on this successful model," referring to XpresTest's airport screening work for the CDC. Govly's Nov. 14 summary put the combined value of the two awards at about $38.8 million.

Advertisement

A Pending $13M Sale and an Investor Tied to Trump's Sons

The contracts may not stay with XWELL. In July, XWELL announced plans to sell XpresTest along with its spa line for $13 million. Ernst told ProPublica the government contracts will follow the subsidiary to the buyer.

The ownership picture drew attention for another reason. In February, an investment fund called American Ventures put about $30 million into XWELL for a stake of roughly 10%. The fund was launched by Dominari Holdings, a financial firm that hired Donald Trump Jr. and Eric Trump as advisers. A spokesperson for the sons said they are "merely passive, minority investors in a fund that invested in this company" and had no involvement in or knowledge of any contract negotiation or procurement. ProPublica's reporting does not show that either son played a role in the awards.

What the Screening Work Covers at Dulles, Atlanta and JFK

The outbreak driving the contracts is caused by Bundibugyo virus and had reached 10,910 confirmed cases and 5,306 confirmed deaths as of Nov. 6, according to the CDC figures cited by MedicalDaily. Nearly all cases are in Congo, with smaller numbers in Uganda, Kenya, Nigeria and France. No U.S. cases have been reported. Unlike the more common Zaire strain, Bundibugyo virus has no licensed vaccine or specific treatment.

Advertisement

Since late on Nov. 3, every passenger boarding an international flight to the U.S. must sign a statement that they have not been in Congo in the previous 21 days, and travelers who were in Congo in that window cannot board commercial flights to the U.S. U.S. citizens and nationals who were in Uganda or South Sudan within 21 days must arrive through Washington Dulles, Hartsfield-Jackson Atlanta or New York's JFK. At those airports, travelers are escorted to a screening area, answer questions about travel and symptoms, have their temperatures checked and are observed for signs of illness.

Because Ebola can take up to 21 days to cause symptoms, a traveler can be infected but healthy at the gate. That makes follow-up monitoring, accurate contact information and clean handoffs to health departments as important as the airport check itself.

What It Means for Contractors

The XpresTest awards show how an urgent public-health requirement can move work to a vendor with an existing operational footprint, even one without direct experience in the specific threat. Firms with airport, logistics or testing infrastructure already in place for federal clients may be well placed to compete for emergency work when an outbreak escalates.

The dispute over how the CDC award was competed carries a lesson for both sides of the table. Govly framed it directly: the discrepancy highlights "the importance of documenting the basis for award method, qualification assessments, and performance-risk evaluations in urgent public-health procurements." When an agency invokes urgency to justify a sole-source award, the justification and the vendor's public statements should match; when they don't, the award becomes a target for oversight and press scrutiny.

Companies pursuing airport screening or international outbreak-response work should be ready to substantiate relevant disease-response experience and operational capacity. Govly noted that these awards do not identify a new solicitation, so there is no open opportunity tied to this coverage. Contractors should also watch how the awards transfer once a buyer for XpresTest is named.

Finally, procurement and compliance teams may want to review ownership and investor disclosures alongside standard ethics checks, while keeping reported associations separate from evidence of interference. In this case, the reporting establishes an investor connection but not any role in the awards.

Sources